The Bench-to-Bedside (B2B) Program funds research teams seeking to translate basic scientific findings into therapeutic interventions for patients and to increase understanding of important disease processes. B2B teams involve basic and clinical researchers, often from different NIH Institutes and Centers. Learn more about an innovative NIH program, Bench-to-Bedside from a researcher who has used it. Bench-to-Bedside breaks down the traditional silos between basic and clinical researchers in biomedical research that can hinder progress toward finding new therapeutics for patients in need. The NIH Bench-to-Bedside program, originally established in 1999 to integrate the work of basic and clinical intramural scientists and since 2006 open to partnerships between intramural and extramural programs, is soliciting proposals for the next cycle of funding.
The NIH Bench-to-Bedside Program is soliciting proposals for the next funding cycle. Once again, CTSAs, AIAMC (Alliance for Independent Academic Medical Centers) and NIH investigators will be able to initiate applications jointly for Bench-to-Bedside research projects. 20 Million NIH Grant to Support Clinical and Bench-to-Bedside Research. This innovative program integrates experiences from a summer Institute into classroom action during the school year. Current Florida and NIH initiatives in translational research (NIH Roadmap for Medical Research) require that today’s students understand, and are academically prepared for, the research, clinical and technical positions increasingly available in the continuum from basic research to marketable medicines, diagnostics and devices. Our proposal, Biomedical Explorations: Bench to Bedside, includes science and education partners in an innovative program available for graduate credit leading to a Certificate in Biotechnology Education.
UC has been awarded 16.7 million from the NIH to continue to enhance its abilities in translating basic scientific discoveries from bench to bedside. From Lab Bench to Bedside: Accelerating the Commercialization of Biomedical Innovations. NIH will evaluate the pilot I-Corps program by determining whether participants are more successful in applying and receiving Phase II SBIR/STTR awards, assessing how well the participation in I-Corps served the business needs of the company and long term, in attracting follow-on funding, and ultimately, commercializing their inventions. NIH Bench-to-Bedside Pioneer Award recognizes how basic science can lead to breakthrough and technology achievement that results in medical and industry driven products. In addition to several NIH leaders, the Program and Award committee is composed of world- renowned Experts and leaders in the field.
The PhD program focuses on biomedical and clinical research that relate directly to developing new therapies for patients. Pharmacology Training Program: From Bench to Bedside. The Pharmacology pre-doctoral graduate student training program is supported due to NIH T32 GM099608 grant funding. Advancing medical breakthroughs from bench to bedside. 62 U.S. medical research institutions receive CTSA program funding from the NIH. NIH BrIDGs program helps overcome research roadblocks. NIH Public-Private Partnerships to Bring Therapies from Bench to Bedside:.